Rishob Dasgupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rishob Dasgupta has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ramsay Hafer
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
1 shared publication - Sherry Yang
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania
1 shared publication - Teresa Duong
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
1 shared publication - Thomas Z. Rohan
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA
1 shared publication
Latest Publications
- Open Access
- 9 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1110
Hidradenitis Suppurativa Is Associated with an Increased Risk of Adverse Cardiac Events and All-Cause Mortality
Background: Hidradenitis suppurativa (HS) has been previously associated with greater rates of major adverse cardiac events (MACEs) compared to the general population. This study aims to better elucidate the association between HS, MACEs, and other cardiovascular diseases. Methods: We utilized TriNetX, a global database of electronic health records, to conduct a retrospective cohort study. HS patients were matched on demographic and cardiovascular disease risk factors to both healthy and psoriasis groups as controls. Results: After adjusting for cardiovascular disease risk factors, HS patients had a relative risk (RR) (95% CI) of 2.06 (1.83–2.32) for myocardial infarction, 1.62 (1.44–1.82) for ischemic stroke, 2.21 (2.04–2.40) for heart failure, 1.95 (1.84–2.07) for MACEs, and 2.57 (2.34–2.83) for all-cause mortality compared to healthy controls. When comparing HS patients to matched psoriasis controls, HS patients had an RR of 1.31 (1.17–1.47) for myocardial infarction, 1.04 (0.93–1.16) for ischemic stroke, 1.24 (1.15–1.34) for heart failure, 1.16 (1.09–1.22) for MACEs, and 1.38 (1.27–1.5) for all-cause mortality. Herein, we demonstrate that patients with HS have increased rates of all cardiovascular diseases investigated when compared to healthy and psoriasis controls, even after adjusting for cardiovascular disease risk factors. Conclusions: These findings highlight the potential benefit in screening for and managing modifiable cardiovascular risk factors in HS patients.
- 9 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1110
Open AccessHidradenitis Suppurativa Is Associated with an Increased Risk of Adverse Cardiac Events and All-Cause Mortality
Background: Hidradenitis suppurativa (HS) has been previously associated with greater rates of major adverse cardiac events (MACEs) compared to the general population. This study aims to better elucidate the association between HS, MACEs, and other cardiovascular diseases. Methods: We utilized TriNetX, a global database of electronic health records, to conduct a retrospective cohort study. HS patients were matched on demographic and cardiovascular disease risk factors to both healthy and psoriasis groups as controls. Results: After adjusting for cardiovascular disease risk factors, HS patients had a relative risk (RR) (95% CI) of 2.06 (1.83–2.32) for myocardial infarction, 1.62 (1.44–1.82) for ischemic stroke, 2.21 (2.04–2.40) for heart failure, 1.95 (1.84–2.07) for MACEs, and 2.57 (2.34–2.83) for all-cause mortality compared to healthy controls. When comparing HS patients to matched psoriasis controls, HS patients had an RR of 1.31 (1.17–1.47) for myocardial infarction, 1.04 (0.93–1.16) for ischemic stroke, 1.24 (1.15–1.34) for heart failure, 1.16 (1.09–1.22) for MACEs, and 1.38 (1.27–1.5) for all-cause mortality. Herein, we demonstrate that patients with HS have increased rates of all cardiovascular diseases investigated when compared to healthy and psoriasis controls, even after adjusting for cardiovascular disease risk factors. Conclusions: These findings highlight the potential benefit in screening for and managing modifiable cardiovascular risk factors in HS patients.